Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Regarding the UChicago PR, Dr. Tung's experience at UCLA was highlighted and his usage of RMN was noted as follows
"He performed dozens of procedures with the Niobe system while at UCLA, 85% of which were for VT ablation (a particularly complex procedure), citing the system’s ability to access every area of the left ventricle."
He started heading up the UCLA VT program in 2009. I am not sure when the system was installed and also when ucla upgraded to the latest generation system which is much quicker with catheter navigation. Still dozens of procedures over multiple years using the magnetic system doesn't seem congruent to the "expert" label when top USA centers do a few hundred VT ablations a year although not all of them robotically.
U. of Chicago installation PR today. Looks like it is finally going live.
http://ir.stereotaxis.com/phoenix.zhtml?c=179896&p=irol-newsArticle&ID=2185138
This was known from January PR with listing of Magnetic VT trial sites.
http://ir.stereotaxis.com/phoenix.zhtml?c=179896&p=irol-newsArticle&ID=2128166
The PR reads like a new installation but it is an upgrade of an existing older system installed in 2009. Is one upgrade worth an increase of $5M in market cap? If so, the company better get more going. I doubt the magnitude and longevity of this run up.
IMO there needs to an hourly evaluation of his performance.
Just kicking the tires here. Dew - I understand what you are saying with regards to RT002 having the best potential here and that RT001 should not have been a priority in the first place. However, I assume that the company had prioritized RT001 ahead of RT002 for reasons that is inconsistent with RT002 having better clinical potential. Why did the company do that in your view? Until I understand that, it is hard for me to be excited about anything that the company does.
I found Tesla's statement regarding the non-detection of the tractor trailer odd.
"Neither Autopilot nor the driver noticed the white side of the tractor trailer against a brightly lit sky, so the brake was not applied."
I drive a car that has multiple sensors that help with collision avoidance. The sensing is not based solely on detecting visible spectrum sensors. There are infrared sensors, doppler sensors etc ... and all of them are used as far as I can tell. So TSLA's statement suggest that their sensors only detects the visible spectrum and I find that odd.
His performance is so random. Today he is doing great.
Dew - what is the approximate chair time difference per patient between lyo and liquid? That has to a big driver in the switch, ie savings all around.
Seeing more and more X's in town. Yesterday, saw the new model S with the model 3 front end look and it looks good without the faux grill. Also noticed that you can get matte finishes - that looks nice too but I wonder how long it stays looking nice. I have yet seen a matte finished car age well on the outside.
The PR reads like a summary of the analysts/investor day meeting. Nothing more.
Stock down due to perception that "a not for sale" sign has been posted via strategic review. I like it because it presents an entry opportunity. I bought some and sold some puts.
Companies always have ongoing strategic reviews so I don't know what the correlation is between presented strategic reviews and takeovers. MDVN wasn't for sale either.
I sold my shares (small position) at 57. Kept my June 45/60 strangle where the premiums have shrunk nicely.
SRPT - What do you think of Feuerstein's article conjecturing that FDA is trying to find a compromise that will allow them to approve?
Traders are having a hard time deciding what the central value ought to be prior to patent decision. Premiums are staying about the same while the stock whipsaws. My guess is that it is somewhere in the range of 40-45 based upon the pricing of 30P and 60C.
There is huge volatility here. Options expiring 2 weeks is pricing in moves of ~10 either up or down. Option pricing seems to suggest a binary event soon for whatever reason.
Cardiostim conference next week. "old dog"
16:00 - 17:30
230 - MAGNETIC NAVIGATION – IS THERE LIFE IN THE OLD DOG YET?
Room 1.6 / Iris - Level 1 / Méditerranée
Session
Co-Chair : S. Ernst (London, GBR), G. Nölker (Bad Oeynhausen, DEU)
JOINT SESSION SCRN (SOCIETY OF CARDIAC ROBOTIC NAVIGATION)
16:00
230-01
Ablation of Atrial Fibrillation Using the Magnetic Navigation System: New Developments
P. Ricard (Nice, FRA)
16:15
230-02
Role of Magnetic Guidance to Reduce Radiation Exposure in Ablation Procedures
D. Bastian (Nürnberg, DEU)
16:30
230-03
Stress Levels in the Operators - Do Magnetic Navigators Sleep Better?
B. Schwagten (Antwerp, BEL)
16:45
230-04
Remotely Directed Lasso-Catheters – The Final Piece of Jigsaw in Magnetic Procedures?
G. Tomassoni (Lexington, USA)
17:00
230-05
Is There Still Room for Manual Ablation in Ventricular Tachycardias?
T. Szili-Torok (Rotterdam, NLD)
The big news is that supercharging the Model 3 will now be an option because of economics according to Musk. Looks like a mistake in mispricing at $35K and an indication of the low profit margin. The hoped for savings for manufacturing batteries at gigafactory is also in question now. Love the S. X is flawed because of doors (eliminating possibility for racks). 3 is now facing pricing issue. All IMO.
Sales growth is almost completely dependent on Japanese sales according CEO during Q&A as sales elsewhere trickles in. With all the positive comments regarding trends in Japan, only 4 systems have been shipped in 2 years. Stock remains stuck in 1st gear and going nowhere for another Q if not longer.
CC transcript - http://seekingalpha.com/article/3973286-stereotaxis-stxs-ceo-bill-mills-q1-2016-results-earnings-call-transcript?part=single
$150 has the same odds as $260 by December expiration according to option prices.
Laid an egg in Q1. No capital sales. Only thing good was flattening of total utilization but that really needs to be ramping up proportionally to increasing installed base.
Great article.
Natale interview - RMN usage and how he sees the technology evolving.
http://www.eplabdigest.com/articles/Value-and-Potential-Remote-Magnetic-Navigation-EP-Interview-Dr-Andrea-Natale
Options market pricing in a move of +/- $5 at May expiration. In the last expiration, option market priced in +/- $9 for FDA panel decision and the price has moved up around $10 after the decision. IMO option traders have done a decent job bracketing the stock reaction to FDA decisions.
How does GILD's decision to license Indian generic companies affect opportunities in the far east? IMO, it will be a struggle to get non-generic pricing in China.
http://www.gilead.com/news/press-releases/2014/9/gilead-announces-generic-licensing-agreements-to-increase-access-to-hepatitis-c-treatments-in-developing-countries
Baker Brothers comments on seeking alpha - not sure if these are the real Baker Brothers or impersonators. Below posted on 4/3 after the Lund PR.
>>>>
bakerbros
Comments (18)| + Follow | Send Message
pump n dump STXS
>>>>
The stock has held up well but leaves behind a gap at 1.13
BLUE - http://finance.yahoo.com/news/bluebird-bio-reports-interim-clinical-124200696.html
cc after hours.
I commented on the BSGM previously.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121423859
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121433739
Also Asirvatham of Mayo seemed puzzled by the PR hyping enhanced Mayo collaboration when asked about it. Besides, there are plenty of tools constantly being developed to increase resolution and noise has not been an issue with the mapping tools being used now. See for example BSX Rhythmia catheter.
Lithium - Bolivia is sitting pretty.
Nibbled some today but momo may take this down to $30. If there is a disaster still hidden from view, I suppose it can go all the way back to where the run started early last year. How do your numbers compare with the range of earnings estimates 3.63-5.16?
re "cash cow"
I love the cars and my town is overflowing with them. My buddy just replaced his Audi and got the s70d. He is my beta tester and loves the car. Supercharging is major issue right now and he needs to burn into memory that he needs to charge at home before driving 60 miles out of town If they are having such trouble with existing S sales as it relates to supercharging, they really need to ramp up charging infrastructure. Everybody including me thought supercharging will be an option for the 3. I think it would have been better if there was a nominal cost so that it doesn't get abused. Back to cash cow - I see charging infrastructure as capital intensive and tesla cannot skimp on it.
Regarding the recent PR's, the first one regarding the Connecticut hospital reaching the 1000 procedure milestone doesn't seem very news worthy as it took 8 years to get there. The newest installations (4th generation) are getting used more frequently because they are more intuitive with short learning curve. The last PR was way more important as it relates to the physical burden of long procedures and career longevity. It takes a huge amount of training/practice and years for EPs to get really good at complex ablations. If they are doing it manually, their career is already 2/3 of the way to the end of their career based upon the age and experience of the current crop of elite experts. Stock finally pulling back as expected.
“On a personal note, the convenience and ease of use associated with the Niobe system alleviates much of the physical burden related to these complex procedures, enabling me to continue practicing electrophysiology longer than expected,” said Dr. Yuan, who performed his first procedure using the Niobe system in late 2011 and has since completed more than 300 cases.
How good do results have to be to compete with AGN?
Define lame and tell us why your posts aren't.
I sold the shares added during the warrant exercise period. Will wait for a pull back towards gap. HNSN moved too for no apparent reason after filing detailing deemed dividend. I sold there too (short via credit spread).
I played this on the short side. I doubt there is anything positive going here in either interventional cardiology or electrophysiology.
IMO. Looks like thumbs up from the panel. Increased efficacy and within the range of elevated mortality HR as prior randomized trials (Dr. Stone's presentation on mortality data in trials of prior anti-psychotics).
Went through Biosig's S-1 and also idea germination back in 2004 (Recom Managed Systems, Signal Life). S1 link below. I don't see them proposing anything new and the guy that started this stuff at UCLA is no longer associated with Biosig. EPs are a little gullible when it comes putting their names on "science" projects that are really primarily intended to raise money. Mayo's name dropping is not supported by release of ANY results. I don't understand how Biosig has a market cap of $25 million with vapor ware that doesn't past a smell test. STXS as an example has a mc of $23M and their tech is very strong for VT mapping and ablation and as good as expert manual hands in AF mapping/ablations.
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=11257074
http://www.heartrhythmjournal.com/article/S1547-5271(06)01185-4/abstract
Those are all optional tools dependent patient characteristics and procedure type. Contact force catheters helps mostly with fellows coming up on learning curve. In the most experienced centers, CF does no better than SF, actually slightly worse in AF and significantly worse in VT. Probably because both commercial versions are relatively stiff. And oblique angle error in contact force is an issue. Still the additional data over conventional manual is nice. However, using force to establish stability can result in false signals so mapping is still left to specialised catheters, when precision is required, that have different biophysics than the ablation catheter that tries to get to the same spot for substrate ablation. All those complexities are the reasons that cryoballoon is taking big bites of market share especially at lower volume centers even at unacceptably high risk of phrenic nerve palsy. The buyouts of Topera, Cardio Insight, Ablation Frontiers, etc .... has made a lot of EPs wealthy for technology that is still to be proven. Biosig like others seems to be a vehicle for some to get on that gravy train. At least is not HIFU or laser balloon where unwitting human guinea pigs are put on the line.
Reads like a bunch of hype and then at the bottom you find out the company to proposing some noise cancellation algorithm to reprocess mapping data. The example shown looks like a far field tracing compared to a bipolar tracing. It had nothing to do with signal processing. A major source of measurement error is the inability of the endocardial electrodes to maintain stable contact with heart tissue. Systolic motion introduces about a 5mm translational and rotational error and respiration adds another 5 mm. That's the more important problem to first solve. Biosig will just be garbage in garbage out unless the former issue is dealt with.